182 related articles for article (PubMed ID: 36333206)
1. Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: A COMPERA analysis.
Rosenkranz S; Pausch C; Coghlan JG; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Delcroix M; Ghofrani HA; Ewert R; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Scelsi L; Neurohr C; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Remppis BA; Skride A; Jureviciene E; Gumbiene L; Miliauskas S; Löffler-Ragg J; Lange TJ; Olsson KM; Hoeper MM; Opitz C
J Heart Lung Transplant; 2023 Jan; 42(1):102-114. PubMed ID: 36333206
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.
Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Rosenkranz S; Lange TJ
J Heart Lung Transplant; 2022 Jul; 41(7):971-981. PubMed ID: 35430147
[TBL] [Abstract][Full Text] [Related]
3. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.
Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Park DH; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Lange TJ; Rosenkranz S
Eur Respir J; 2022 Jul; 60(1):. PubMed ID: 34737226
[TBL] [Abstract][Full Text] [Related]
4. Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.
Hoeper MM; Dwivedi K; Pausch C; Lewis RA; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Park DH; Ghofrani HA; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Lange TJ; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Swift AJ; Thompson AAR; Elliot CA; Rosenkranz S; Condliffe R; Kiely DG; Halank M
Lancet Respir Med; 2022 Oct; 10(10):937-948. PubMed ID: 35777416
[TBL] [Abstract][Full Text] [Related]
5. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.
Wronski SL; Mordin M; Kelley K; Anguiano RH; Classi P; Shen E; Manaker S
Lung; 2020 Feb; 198(1):65-86. PubMed ID: 31722043
[TBL] [Abstract][Full Text] [Related]
6. Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities a cross-sectional cohort study with survival follow-up.
Xanthouli P; Koegler M; Marra AM; Benjamin N; Fischer L; Eichstaedt CA; Harutyunova S; Nagel C; Grünig E; Egenlauf B
Respir Res; 2020 May; 21(1):127. PubMed ID: 32448256
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension.
Mauritz GJ; Rizopoulos D; Groepenhoff H; Tiede H; Felix J; Eilers P; Bosboom J; Postmus PE; Westerhof N; Vonk-Noordegraaf A
Am J Cardiol; 2011 Dec; 108(11):1645-50. PubMed ID: 21890089
[TBL] [Abstract][Full Text] [Related]
8. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.
Fritz JS; Blair C; Oudiz RJ; Dufton C; Olschewski H; Despain D; Gillies H; Kawut SM
Chest; 2013 Feb; 143(2):315-323. PubMed ID: 22814814
[TBL] [Abstract][Full Text] [Related]
9. Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry.
Hoeper MM; Pausch C; Grünig E; Klose H; Staehler G; Huscher D; Pittrow D; Olsson KM; Vizza CD; Gall H; Benjamin N; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Rosenkranz S; Ewert R; Kaemmerer H; Lange TJ; Kabitz HJ; Skowasch D; Skride A; Jureviciene E; Paleviciute E; Miliauskas S; Claussen M; Behr J; Milger K; Halank M; Wilkens H; Wirtz H; Pfeuffer-Jovic E; Harbaum L; Scholtz W; Dumitrescu D; Bruch L; Coghlan G; Neurohr C; Tsangaris I; Gorenflo M; Scelsi L; Vonk-Noordegraaf A; Ulrich S; Held M
J Heart Lung Transplant; 2020 Dec; 39(12):1435-1444. PubMed ID: 33082079
[TBL] [Abstract][Full Text] [Related]
10. Risk assessment and survival of patients with pulmonary hypertension: Multicenter experience in Turkey.
Yaylalı YT; Başarıcı I; Kılıçkıran Avcı B; Meriç M; Sinan ÜY; Şenol H; Küçükoğlu MS; Öngen Z
Anatol J Cardiol; 2019 Jun; 21(6):322-330. PubMed ID: 31142721
[TBL] [Abstract][Full Text] [Related]
11. Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study.
Escribano-Subias P; López R; Almenar L; Lázaro M; Forn I; Torrent A; Blanco I; Barberà JA;
BMC Pulm Med; 2020 Jun; 20(1):154. PubMed ID: 32487059
[TBL] [Abstract][Full Text] [Related]
12. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
Hendriks PM; van de Groep LD; Veen KM; van Thor MCJ; Meertens S; Boersma E; Boomars KA; Post MC; van den Bosch AE
Am Heart J; 2022 Aug; 250():34-44. PubMed ID: 35533723
[TBL] [Abstract][Full Text] [Related]
14. Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension.
Stolfo D; Barbisan D; Ameri P; Lombardi CM; Monti S; Driussi M; Zovatto IC; Gentile P; Howard L; Toma M; Pagnesi M; Collini V; Bauleo C; Guglielmi G; Adamo M; D'Angelo L; Nalli C; Sciarrone P; Moschella M; Zorzi B; Vecchiato V; Milani M; Di Poi E; Airò E; Metra M; Garascia A; Sinagra G; Lo Giudice F
J Heart Lung Transplant; 2023 Aug; 42(8):1082-1092. PubMed ID: 37005100
[TBL] [Abstract][Full Text] [Related]
15. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension.
Rhodes CJ; Wharton J; Howard LS; Gibbs JS; Wilkins MR
Heart; 2011 Jul; 97(13):1054-60. PubMed ID: 21558476
[TBL] [Abstract][Full Text] [Related]
16. Methamphetamine-associated pulmonary arterial hypertension: data from the national biological sample and data repository for pulmonary arterial hypertension (PAH Biobank).
Charoenpong P; Dhillon N; Murnane K; Goeders N; Hall N; Keller C; Bhuiyan MAN; Walter R
BMJ Open Respir Res; 2023 Dec; 10(1):. PubMed ID: 38061804
[TBL] [Abstract][Full Text] [Related]
17. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
[TBL] [Abstract][Full Text] [Related]
18. Impact of diabetes mellitus on disease severity and patient survival in idiopathic pulmonary arterial hypertension: data from the Polish multicentre registry (BNP-PL).
Jonas K; Kurzyna M; Mroczek E; Chrzanowski Ł; Mularek-Kubzdela T; Skoczylas I; Błaszczak P; Grześk G; Mizia-Stec K; Kuśmierczyk B; Kamiński K; Lewicka E; Peregud-Pogorzelska M; Tomaszewski M; Jacheć W; Gąsior Z; Pawlak A; Ryczek R; Pruszczyk P; Doboszyńska A; Widejko-Pietkiewicz K; Zabłocka W; Waligóra M; Kopeć G
Cardiovasc Diabetol; 2023 Jul; 22(1):177. PubMed ID: 37443009
[TBL] [Abstract][Full Text] [Related]
19. N-terminal pro-B-type natriuretic peptide as an indicator of disease severity in a heterogeneous group of patients with chronic precapillary pulmonary hypertension.
Andreassen AK; Wergeland R; Simonsen S; Geiran O; Guevara C; Ueland T
Am J Cardiol; 2006 Aug; 98(4):525-9. PubMed ID: 16893710
[TBL] [Abstract][Full Text] [Related]
20. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
